In the gleaming landscape of China’s medical aesthetics market, a shadow economy is thriving on the country’s most popular e-commerce platforms. An investigation into JD.com, Taobao, and Xiaohongshu reveals a systemic failure to regulate the sale of Class III medical devices—specifically injectable skin boosters known as "Shuiguang" needles. These products, which often contain hyaluronic acid and anesthetic lidocaine, are legally restricted to licensed medical institutions, yet they are currently being sold directly to individual consumers like ordinary skincare.
This trend is fueled by a broader "consumer downgrading" across China, where budget-conscious shoppers are abandoning high-end clinics for DIY treatments or unlicensed "studios." On JD’s "Jingxi" platform and various Tmall storefronts, professional-grade injectables are listed at a fraction of clinical prices. While some listings include perfunctory warnings that the products are for professional use only, the investigative findings show that individual buyers can complete purchases without providing any medical credentials or institutional verification.
The supply chain for these illicit sales is a complex web of arbitrage and questionable authenticity. Some sellers claim to "flip" genuine stock diverted from legitimate hospitals and clinics, moving inventory through medical device trading companies to reach the retail market. However, industry insiders warn that the lack of oversight makes these channels a breeding ground for counterfeits and "grey market" imports that bypass safety standards, leading to a secondary industry of amateur "authenticity appraisers" on social media.
Underneath the convenience of e-commerce lies a mounting public health crisis. Medical professionals report a surge in complications, including facial infections, granulomas, and permanent scarring, resulting from improper injection techniques or contaminated products. Because these procedures are often performed in unregulated environments like nail salons, gyms, or private homes, victims have little to no legal recourse when treatments go wrong, leaving them to navigate a "regulatory vacuum" where tech giants and local enforcers seem equally paralyzed.
Chinese law is explicit: Class III medical devices require the highest level of oversight, and platforms are responsible for monitoring and reporting illegal sales. Yet, by allowing these high-risk products to be marketed alongside face masks and lotions, platforms like Xiaohongshu and Alibaba’s Taobao are effectively enabling unlicensed medical practice. As the industry matures, the gap between strict paper regulations and the chaotic reality of digital retail remains a significant hurdle for China’s healthcare authorities.